Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer

(MedPage Today) -- Findings from the phase Ib/II ELEVATE trial presented at the San Antonio Breast Cancer Symposium demonstrated the potential of the oral selective estrogen receptor degrader elacestrant (Orserdu) in combination with various targeted...